Researchers outline tool to spot duplicate systematic reviews

By AI, Created 12:43 PM UTC, May 16, 2026, /AGP/ – A 2026 protocol details the development of a Systematic Review Duplication tool to measure when intervention-based reviews largely overlap, using a four-domain framework and staged validation. The goal is to help researchers, editors, and guideline teams avoid redundant evidence syntheses and focus on reviews that add real value.

Why it matters: - Systematic reviews are multiplying fast, and many now cover the same interventions with overlapping evidence. - Duplicate reviews can create confusion, waste research effort, and produce conflicting conclusions for clinicians and policymakers. - A dedicated duplication tool could help determine whether a new review fills a real gap or repeats existing work.

What happened: - Researchers from the Affiliated Traditional Chinese Medicine Hospital of Guangzhou Medical University, Lanzhou University, and Hong Kong Baptist University published a 2026 protocol for the Systematic Review Duplication (SRD) tool in Evidence-Based Chinese Medicine and Technology Assessment. - The paper has DOI 10.26599/eCMTA.2026.9570031. - The article was received Dec. 16, 2025, revised Feb. 18, 2026, and accepted March 20, 2026. - The protocol focuses on intervention-based systematic reviews addressing the same disease or condition.

The details: - The SRD tool is designed to compare pairs of systematic reviews and judge whether overlap reflects meaningful replication or avoidable redundancy. - The developers will build the tool in three phases: preparatory work, tool development, and dissemination. - The framework uses four domains: research topic, research methods, research results, and methodological quality. - The output is intended to be a qualitative duplication profile, not a simple yes-or-no label. - Development steps include literature-based item generation, pilot testing, a two-round modified Delphi process, consensus meetings, and reliability testing. - The pilot will use 40 systematic reviews across 17 disease categories. - The final tool is expected in both web-based and Excel-based formats. - The team plans a full version for in-depth assessment and a simplified version for rapid screening. - Existing tools such as PRISMA 2020, AMSTAR 2, and ROBIS assess reporting quality, rigor, and bias, but they were not built to measure duplication between reviews. - The number of systematic reviews indexed in PubMed rose from an estimated 1,432 per year in 2000 to 29,073 in 2019. - The paper argues that this growth has increased redundancy and inconsistency across reviews addressing the same question.

Between the lines: - The protocol frames duplication as a quality problem, not just a volume problem. - The four-domain design suggests the team wants to assess overlap more holistically than current review checklists do. - The planned qualitative profile may be more useful than a binary duplicate/non-duplicate result in complex research areas. - The authors position the tool as a filter for novelty in a crowded evidence landscape, where repeated synthesis can weaken rather than strengthen confidence.

What’s next: - The team will test and refine the SRD tool through Delphi rounds, consensus sessions, and reliability checks. - If validation succeeds, researchers could use the tool before starting a review to see whether a meaningful gap still exists. - Editors and peer reviewers could use it to judge novelty and contribution. - Guideline developers and health technology assessment teams could use it to choose among overlapping reviews. - The authors suggest the framework may be especially useful in fields with varied interventions and outcome measures.

The bottom line: - The SRD tool aims to give the evidence-synthesis field a way to spot unnecessary duplication before more time and resources go into another near-identical review.